Here are the 424B prospectus supplements from Regentis Biomaterials Ltd. (RGNT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow RGNT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RGNT filings page.
Regentis Biomaterials Ltd. is registering for resale by existing investors up to 3,807,143 Ordinary Shares. This includes 1,844,543 shares sold in a June 2026 private placement plus shares issuable upon exercise of Pre-Funded, Ordinary and Placement Agent Warrants. Ordinary Shares outstanding were 7,023,921 as of July 13, 2026; this is a baseline figure, not the amount being offered.
Regentis will not receive proceeds from selling shareholders’ resales. It may receive approximately $8.21 million only if all Offered Warrants are exercised for cash. Regentis is a regenerative medicine company developing GelrinC, an off-the-shelf hydrogel implant for articular knee cartilage injuries, currently in a pivotal trial in the United States and Europe.